Abstract:Efforts to get naloxone into the hands of opioid users, their loved ones, and first responders before an opioid overdose occurs seem to be succeeding, according to speakers at the federally convened w...Efforts to get naloxone into the hands of opioid users, their loved ones, and first responders before an opioid overdose occurs seem to be succeeding, according to speakers at the federally convened workshop “Exploring Naloxone Uptake and Use,” held July 1–2 in Silver Spring, Maryland. But success comes with a price, and that price does not seem to be headed downward. When Kaleo Inc. launched its Evzio 1-mg/mL naloxone hydrochloride autoinjector in July 2014, the company priced each carton at about four times the invoice price of a box of same-strength 2-mL naloxone syringes, said Matthew Rosenberg, an analyst at FDA. The new drug–device combination product has an electronic audio system that voices step-by-step instructions on injecting the drug into a muscle or subcutaneous tissue. Each carton contains two 0.4-mg/0.4 mL naloxone hydrochloride injection autoinjectors and a reusable trainer device. About two months after the naloxone autoinjector became available, the invoice price for that 10-pack of naloxone syringes, by Amphastar Pharmaceuticals Inc., increased by about 60%, Rosenberg said.Read More
Publication Year: 2015
Publication Date: 2015-08-20
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot